Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The design of modified oligonucleotides that combine in one molecule several therapeutically beneficial properties still poses a major challenge. Recently a new type of modified mesyl phosphoramidate (or µ-) oligonucleotide was described that demonstrates high affinity to RNA, exceptional nuclease resistance, efficient recruitment of RNase H, and potent inhibition of key carcinogenesis processes in vitro. Herein, using a xenograft mouse tumor model, it was demonstrated that microRNA miR-21-targeted µ-oligonucleotides administered in complex with folate-containing liposomes dramatically inhibit primary tumor growth via long-term down-regulation of miR-21 in tumors and increase in biosynthesis of miR-21-regulated tumor suppressor proteins. This antitumoral effect is superior to the effect of the corresponding phosphorothioate. Peritumoral administration of µ-oligonucleotide results in its rapid distribution and efficient accumulation in the tumor. Blood biochemistry and morphometric studies of internal organs revealed no pronounced toxicity of µ-oligonucleotides. This new oligonucleotide class provides a powerful tool for antisense technology.

Original publication

DOI

10.1073/pnas.2016158117

Type

Journal article

Journal

Proc Natl Acad Sci U S A

Publication Date

22/12/2020

Volume

117

Pages

32370 - 32379

Keywords

DNA modification, antisense oligonucleotide, mesyl oligonucleotide, oncogenic microRNA, phosphorothioate, Amides, Animals, Antineoplastic Agents, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Male, Melanoma, Mice, SCID, MicroRNAs, Molecular Targeted Therapy, Oligonucleotides, Antisense, Phosphoric Acids, Tissue Distribution, Xenograft Model Antitumor Assays